Amgen Inc (NASDAQ:AMGN)

203.20
Delayed Data
As of 4:00pm ET
 +0.86 / +0.43%
Today’s Change
163.31
Today|||52-Week Range
204.42
+16.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$131.0B

Company Description

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Contact Information

Amgen, Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799
P:(805) 447-1000
Investor Relations:
(805) 447-1060

Employees

Shareholders

Mutual fund holders47.45%
Other institutional38.04%
Individual stakeholders0.81%

Top Executives

Robert A. BradwayChairman & Chief Executive Officer
Esteban SantosExecutive Vice President-Operations
David W. MelineCFO, Chief Accounting Officer & Executive VP
David M. ReeseExecutive Vice President-Research & Development
Cynthia M. PattonChief Compliance Officer & Senior Vice President